Medigene AG
MDG1.DEDrugs in Pipeline
8
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
Condylomata Acuminata
Sinecatechins 10%
Carcinoma, Basal Cell
EndoTAG®-1
Liver Cancer
WT1/PRAME vaccination
Acute Myeloid Leukemia
NV1020
Colorectal Cancer
Gemcitabine alone
Adenocarcinoma
EndoTAG-1 + paclitaxel
Breast Neoplasms
G207, an oncolytic virus
Glioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Polyphenon E Ointment 10%, Polyphenon E Ointment 15% | Phase 3 | Condylomata Acuminata | - | - |
Sinecatechins 10% | Phase 3 | Carcinoma, Basal Cell | - | - |
EndoTAG®-1 | Phase 2 | Liver Cancer | - | - |
WT1/PRAME vaccination | Phase 2 | Acute Myeloid Leukemia | - | - |
NV1020 | Phase 2 | Colorectal Cancer | - | - |
Gemcitabine alone | Phase 2 | Adenocarcinoma | - | - |
EndoTAG-1 + paclitaxel | Phase 2 | Breast Neoplasms | - | - |
G207, an oncolytic virus | Phase 2 | Glioma | - | - |
Frequently asked questions
What is in Medigene AG's drug pipeline?→
CatalystAlert tracks 8 drug candidates in Medigene AG's (MDG1.DE) pipeline across Phase 3, Phase 2. Its lead program is Polyphenon E Ointment 10%, Polyphenon E Ointment 15% (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Medigene AG's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Medigene AG (MDG1.DE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MDG1.DE biotech catalysts?→
Add MDG1.DE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Medigene AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.